



RADIUS HEALTH, INC.



*BANK OF AMERICA MERRILL LYNCH
HEALTHCARE CONFERENCE*

May 15, 2018

NASDAQ: RDUS

Radius[®]

Safe Harbor

Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends or strategies and other financial or business matters, including regarding the commercialization of TYMLOS® (abaloparatide) injection in the U.S., the development and potential commercialization of our product candidates, clinical trial results, regulatory actions and communications, potential collaborations, future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when used in this presentation, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predicts”, “targets” and similar expressions and their variants, as they relate to Radius Health, Inc. (“Radius”) or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Radius to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization of TYMLOS in the U.S., or potential commercialization of any of Radius’ proposed product candidates if approved, (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on and challenges to our intellectual property rights; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius’ business, financial conditions and results of operations and could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation are contained under the caption “risk factors” in Radius’ Annual Report on Form 10-K for the period ended December 31, 2017, along with Radius’ other reports filed with the Securities and Exchange Commission. The forward-looking statements in this presentation represent Radius’ estimate as of the date of this presentation only, and Radius specifically disclaims any duty or obligation to update forward-looking statements.

Executing On Key Objectives

TYMLOS Commercial Leadership

- ✓ Q1 sales: \$14.5m; +90% growth over prior quarter
- ✓ Q1 avg 13%* TRx share and avg 31% NBRx** share
- ✓ Growth driven by higher intent to prescribe and stronger commercial access with priority/exclusivity; ESI one-off switch

Expand Abaloparatide Pipeline

- ✓ Initiated Male Osteoporosis Phase 3 (ATOM) Study
- ✓ FDA alignment for abaloparatide-patch Phase 3 bridging study
- ✓ Signed commercial manufacturing agreement with 3M Company

Advance Breast Cancer Pipeline

- ✓ Finalized elacestrant development path based on FDA/EMA feedback
- ✓ Phase 3 study expected to start in 2H 2018




*: Anabolic Osteoporosis Market: Bone building therapies, Forteo and TYMLOS
TRx: Total Scripts measured as Patient Months On Therapy (PMOT); NBRx: New Patients to Brand Drug

Radius Pipeline of Investigational Drugs

	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY REVIEW	MARKET
Abaloparatide-SC Osteoporosis Anabolic Subcutaneous injection	Postmenopausal women (U.S.)					TYMLOS™ (abaloparatide) injection
	Postmenopausal women (EU)					
	Men (Bridging study)					
Abaloparatide Patch Osteoporosis Anabolic Transdermal Patch	Postmenopausal women					
Elacestrant ER+ Breast Cancer Oral SERD	Advanced ER+ / HER2-					
RAD140 HR+ Breast Cancer Oral SARM	Advanced HR+					


TYMLOS U.S. Market Share Continues to Increase in Q1 2018



Source: IQVIA NPA Monthly and New to Brand Monthly, month ending March 2018.
NBRx: New Patients To Brand Drug

* Measured in Patients Month on Therapy (PMOT). Tymlos PMOT (also number of pens) = (IMS Extended Units TRx / 1.56ml)* (30 daily doses / 30 days)
Forteo PMOT = (IMS Extended Units TRx / 2.4ml)* (28 daily doses / 30 days)

TYMLOS Access Rises Across All Segments to ~263 M Covered Lives with 88% of the US Insured Population



- Anabolic patient mix continues shifting toward Commercial, where TYMLOS coverage now exceeds Forteo's
- Focused on increasing access in Medicare Part D with active engagement in 2019 review cycle and additional off-cycle additions for 2018
- Reimbursement obtained for TYMLOS scripts in many Medicare Part D plans with no formulary access



Covered Lives Source: MMIT as of May 8, 2018; Radius Internal
 Payor Mix Source: IQVIA Xponent Data as of April 13, 2018

In FY 2018, RDUS Expects the Anabolic Market to Grow 5% to 7% and TYMLOS to capture avg 19% to 21% of Anabolic Market Share

Anabolic Market * <i>(volume in PMOT)</i>	Q3 2017	Q4 2017	Q1 2018	FY 2018
Anabolic Market Growth (% vs Prior Year)	1%	8%	8%	+ 5% to 7%
TYMLOS NBRx Share (avg %)	11%	19%	31%	
TYMLOS TRx PMOT Share (avg %)	2%	6%	13%	FY Avg 19% – 21%

NBRX: New Patients to Brand Drug

Source: IQVIA. Restated data as of 2018

CONVERSION OF SCRIPTS TO PMOT (Patient Months on Therapy)

- Using unadjusted Total Rx data per IQVIA (IMS) would generate 13 TRxs over twelve months for Forteo, versus 12 for TYMLOS
- Using PMOT adjusts for a cleaner like for like comparison and gives out scripts for a 30 day therapy

Tymlos PMOT (also number of pens) = (IMS Extended Units TRx / 1.56ml)* (30 daily doses / 30 days)

Forteo PMOT = (IMS Extended Units TRx / 2.4ml)* (28 daily doses / 30 days)

Expected Upcoming Milestones

- ✓ Elacestrant clinical regulatory pathway for global registrational study
- ✓ Abaloparatide patch FDA alignment in Jan 2018 and commercial agreement with 3M in Feb 2018
- ✓ Initiation of Phase 3 Abaloparatide Male Osteoporosis Bridging Study in Q1 2018
- Radius Osteoporosis Investor Day (June 8th, NYC)
- CHMP opinion on MAA for abaloparatide-SC*
- Publication of ACTIVEExtend Phase 3 data
- Initiate elacestrant Phase 3, potential global registrational study, in breast cancer in 2H 2018
- Update on RAD140 Phase 1 development program by the end of 2018
- Collaboration agreement for elacestrant combination studies
- Ex-US partnership for abaloparatide

THANK YOU



NASDAQ: RDUS

Radius[®]